New drug SP-624 targets brain waves in depression study
Knowledge-focused
Completed
This completed Phase 1 trial tested whether the experimental drug SP-624 affects brain electrical activity in 26 people — some healthy, some with major depression. Participants took SP-624 or a placebo daily for two weeks. Researchers used EEG and AI to look for changes in brain …
Phase: PHASE1 • Sponsor: Sirtsei Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC